Physician profile
Chanda Sadiq
NPI 1689150690
$2,702.70
in general payments reported to CMS, 2019-2025
28 companies · $1,183 in 2025
The $1,183 reported for 2025 was more than what 86% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $430 · 2024: $1,090 · 2025: $1,183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,660 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,660.20 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $430.98 | 2023-2025 | Wegovy |
| Lilly USA, LLC | $362.09 | 2023-2025 | Jardiance, Mounjaro, Zepbound |
| Exact Sciences Corporation | $223.61 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $174.07 | 2023-2025 | |
| Glaxosmithkline, LLC. | $157.66 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Shield Therapeutics INC | $131.14 | 2023-2025 | Accrufer |
| Dexcom, INC. | $110.27 | 2023-2025 | Dexcom G6 Transmitter |
| Insulet Corporation | $101.20 | 2024-2025 | Omnipod |
| Astrazeneca Pharmaceuticals LP | $99.21 | 2023-2025 | Breztri, Airsupra |
| Amgen INC. | $95.87 | 2023-2025 | Otezla, Repatha, Repatha |
| Merck Sharp & Dohme LLC | $88.40 | 2023-2025 | Gardasil 9, Capvaxive, Gardasil |
| Mannkind Corporation | $76.15 | 2025 | |
| Novartis Pharmaceuticals Corporation | $70.67 | 2024-2025 | |
| Janssen Biotech, INC. | $68.87 | 2023-2024 | Darzalex |
| Astellas Pharma US INC | $59.08 | 2024 | Veozah |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $55.54 | 2024 | Freestyle Libre 3 |
| Boston Scientific Corporation | $54.60 | 2025 | Watchman Flx |
| Sequel Med Tech, LLC | $48.29 | 2025 | Twiist |
| Abbvie INC. | $45.02 | 2025 | |
| Ascensia Diabetes Care US INC. | $42.83 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $40.86 | 2023-2024 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $35.59 | 2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.50 | 2024 | Jardiance |
| Hologic Sales and Service, LLC | $24.70 | 2025 | Aptima |
| Ibsa Pharma INC. | $19.96 | 2024 | Flector, Licart, Tirosint |
| Pharming Healthcare, INC. | $19.42 | 2025 | Ruconest |
| Medtronic, INC. | $18.13 | 2023 | Minimed 780g |
| Cepheid | $14.99 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chanda Sadiq listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.